Bio

Peter Buhl Jensen has 35 years of experience in clinical cancer therapy and as a serial entrepreneur. He is the founder/co-founder of Oncology Venture A/S, TopoTarget A/S which he also led as the CEO. He has also co-founded and CHOSA ApS, and Buhl Oncology ApS and has been key in the development and approval of the cancer drugs Savene® (EU approval 2006, FDA 2007) & Belinostat® (FDA approval 2014).  

Buhl Jensen was the Chief Oncologist and chief executive at the Oncology department at Rigshospitalet (2000-08), and Aalborg University Hospital (2010-11).

Holdings in the Company:  15,506,935* shares, corresponding to approximately 24.7 % of the shares in the company.

Peter Buhl Jensen

CEO

Experience

  • CEO, CHOSA Oncology

  • Founder & CEO, Oncology Venture A/S

  • Founder & CEO, TopoTarget A/S

  • Chief Oncologist & Executive, Rigshospitalet

  • Chief Oncologist & Executive, Aalborg University Hospital

Key Achievements

  • 35+ years in clinical oncology and biotechnology

  • Co-developed the DRP® precision oncology platform

  • Led the development and approval of Savene® and Belinostat®

  • Founded and scaled multiple oncology companies